Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

2.8K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LRRK2 Mutation Alters Dopamine D2 Receptor Localization in Induced Pluripotent Stem Cells-Derived Astrocytes From Parkinson's Disease Patients: Implications for Neuronal Damage.

Journal of neurochemistry·2026
Same author

Regulation between LRRK2 and PP2A signaling in cellular models of Parkinson's disease.

The Biochemical journal·2026
Same author

β-Sitosterol β-D-glucoside (BSSG) triggers intestinal inflammation in zebrafish and mouse models prior to neurodegeneration onset.

Journal of biomedical science·2026
Same author

A Novel Modified Ultrasound-Guided Venipuncture Technique for Non-Tunneled PICC Insertion in a Non-Operating Room Anesthesia (NORA) Setting: A Technical Report with Real-World Experience.

Journal of clinical medicine·2026
Same author

Nuclear ASC speck formation in microglia is associated with inflammasome priming and is exacerbated in LRRK2-G2019S Parkinson's disease.

Neurobiology of disease·2025
Same author

Thrombocytopenia in antiphospholipid syndrome: predictors, prognostic implications, and thrombotic risk in a large cohort study.

Thrombosis research·2025

Related Experiment Video

Updated: Sep 27, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.9K

LRRK2 as a target for modulating immune system responses.

Isabella Russo1, Luigi Bubacco2, Elisa Greggio2

  • 1Biology and Genetics Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Genetics Unit, IRCCS Istituto Centro S. Giovanni di Dio, Fatebenefratelli, Brescia, Italy.

Neurobiology of Disease
|April 15, 2022
PubMed
Summary

Mutations in the Leucine-Rich Repeat Kinase 2 (LRRK2) gene link Parkinson's disease (PD) to immune disorders. LRRK2 inhibitors may offer a disease-modifying strategy for PD patients.

Keywords:
BiomarkersImmune systemInflammationKinase inhibitorsLRRK2Parkinson's disease

More Related Videos

Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

22.7K
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.7K

Related Experiment Videos

Last Updated: Sep 27, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.9K
Assaying the Kinase Activity of LRRK2 in vitro
06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

22.7K
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.7K

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Mutations in the Leucine-Rich Repeat Kinase 2 (LRRK2) gene are linked to Parkinson's disease (PD) and immune-related disorders.
  • LRRK2 plays a significant role in modulating both systemic and central nervous system inflammatory responses.

Purpose of the Study:

  • To review the role of LRRK2 in central and peripheral inflammation in Parkinson's disease and inflammatory disease models.
  • To discuss the potential therapeutic benefits of LRRK2 inhibitors and anti-inflammatory drugs for PD.

Main Methods:

  • Literature review of studies on LRRK2, Parkinson's disease, and inflammation.
  • Analysis of genetic evidence and experimental models linking LRRK2 to immune function.

Main Results:

  • LRRK2 mutations are associated with increased risk and progression of Parkinson's disease.
  • LRRK2 modulates inflammatory pathways relevant to both neurodegenerative and immune disorders.
  • Preclinical data suggest LRRK2 inhibitors can reduce inflammation in relevant models.

Conclusions:

  • LRRK2 is a key player in neuroinflammation and immune system regulation.
  • Targeting LRRK2 with inhibitors presents a promising disease-modifying strategy for Parkinson's disease.
  • Further research into LRRK2's role in inflammation could reveal new therapeutic avenues for PD and other immune-related conditions.